View in EDS

Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.

Saved in:
Bibliographic Details
Title: Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
Authors: Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: palombam@mskcc.org., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Karmali R; Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA., Skarbnik AP; Novant Health Cancer Institute, Charlotte, NC, USA., Abramson JS; Lymphoma Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ardeshna K; University College London Hospitals Biomedical Research Centre, London, UK., Borchmann P; Universität zu Köln, Albertus-Magnus-Platz, Cologne, Germany., Hill BT; Cleveland Clinic, Cleveland, OH, USA., García-Sancho AM; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain., Marcacci G; National Cancer Institute, Fondazione 'G Pascale', IRCCS, Naples, Italy., Rapoport AP; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Cartron G; Montpellier University Hospital Center, UMR CNRS, Montpellier, France., Fleury I; Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada., Izutsu K; National Cancer Center Hospital, Chuo City, Tokyo, Japan., Kamdar M; University of Colorado Cancer Center, Aurora, CO, USA., Mielke S; Departments of Laboratory Medicine and Medicine at Huddinge, Center of Allogeneic Stem Cell Transplantation and Cellular Therapy, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, H5 Laboratories Medicine, Stockholm, Sweden., Barbui AM; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Ortega JLR; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Seville, Spain., Nastoupil LJ; Southwest Oncology, CommonSpirit Mercy, Durango, CO, USA., Ahmed S; MD Anderson Cancer Center, Houston, TX, USA., Bar M; Bristol Myers Squibb, Boudry, Switzerland., Diaz L; Bristol Myers Squibb, Boudry, Switzerland., Furustrand U; Bristol Myers Squibb, Boudry, Switzerland., Diab V; Bristol Myers Squibb, Princeton, NJ, USA., Vedal M; Bristol Myers Squibb, Boudry, Switzerland., Avilion A; Bristol Myers Squibb, Seattle, WA, USA., Kumar J; Bristol Myers Squibb, Princeton, NJ, USA., Nishii R; Bristol Myers Squibb, Princeton, NJ, USA., Colicino S; Bristol Myers Squibb, Boudry, Switzerland., Morschhauser F; Département d'Hématologie, Université de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.
Source: Lancet (London, England) [Lancet] 2026 Mar 07; Vol. 407 (10532), pp. 963-975. Date of Electronic Publication: 2026 Feb 12.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41692020
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Palomba+ML%22">Palomba ML</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: palombam@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Schuster+SJ%22">Schuster SJ</searchLink>; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Karmali+R%22">Karmali R</searchLink>; Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Skarbnik+AP%22">Skarbnik AP</searchLink>; Novant Health Cancer Institute, Charlotte, NC, USA.<br /><searchLink fieldCode="AU" term="%22Abramson+JS%22">Abramson JS</searchLink>; Lymphoma Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ardeshna+K%22">Ardeshna K</searchLink>; University College London Hospitals Biomedical Research Centre, London, UK.<br /><searchLink fieldCode="AU" term="%22Borchmann+P%22">Borchmann P</searchLink>; Universität zu Köln, Albertus-Magnus-Platz, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Hill+BT%22">Hill BT</searchLink>; Cleveland Clinic, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22García-Sancho+AM%22">García-Sancho AM</searchLink>; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Marcacci+G%22">Marcacci G</searchLink>; National Cancer Institute, Fondazione 'G Pascale', IRCCS, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Rapoport+AP%22">Rapoport AP</searchLink>; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Cartron+G%22">Cartron G</searchLink>; Montpellier University Hospital Center, UMR CNRS, Montpellier, France.<br /><searchLink fieldCode="AU" term="%22Fleury+I%22">Fleury I</searchLink>; Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Izutsu+K%22">Izutsu K</searchLink>; National Cancer Center Hospital, Chuo City, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Kamdar+M%22">Kamdar M</searchLink>; University of Colorado Cancer Center, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Mielke+S%22">Mielke S</searchLink>; Departments of Laboratory Medicine and Medicine at Huddinge, Center of Allogeneic Stem Cell Transplantation and Cellular Therapy, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, H5 Laboratories Medicine, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Barbui+AM%22">Barbui AM</searchLink>; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.<br /><searchLink fieldCode="AU" term="%22Ortega+JLR%22">Ortega JLR</searchLink>; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Nastoupil+LJ%22">Nastoupil LJ</searchLink>; Southwest Oncology, CommonSpirit Mercy, Durango, CO, USA.<br /><searchLink fieldCode="AU" term="%22Ahmed+S%22">Ahmed S</searchLink>; MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Bar+M%22">Bar M</searchLink>; Bristol Myers Squibb, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Diaz+L%22">Diaz L</searchLink>; Bristol Myers Squibb, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Furustrand+U%22">Furustrand U</searchLink>; Bristol Myers Squibb, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Diab+V%22">Diab V</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Vedal+M%22">Vedal M</searchLink>; Bristol Myers Squibb, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Avilion+A%22">Avilion A</searchLink>; Bristol Myers Squibb, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Kumar+J%22">Kumar J</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Nishii+R%22">Nishii R</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Colicino+S%22">Colicino S</searchLink>; Bristol Myers Squibb, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Morschhauser+F%22">Morschhauser F</searchLink>; Département d'Hématologie, Université de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 Mar 07; Vol. 407 (10532), pp. 963-975. <i>Date of Electronic Publication: </i>2026 Feb 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41692020
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(25)02435-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 963
    Titles:
      – TitleFull: Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Palomba ML
      – PersonEntity:
          Name:
            NameFull: Schuster SJ
      – PersonEntity:
          Name:
            NameFull: Karmali R
      – PersonEntity:
          Name:
            NameFull: Skarbnik AP
      – PersonEntity:
          Name:
            NameFull: Abramson JS
      – PersonEntity:
          Name:
            NameFull: Ardeshna K
      – PersonEntity:
          Name:
            NameFull: Borchmann P
      – PersonEntity:
          Name:
            NameFull: Hill BT
      – PersonEntity:
          Name:
            NameFull: García-Sancho AM
      – PersonEntity:
          Name:
            NameFull: Marcacci G
      – PersonEntity:
          Name:
            NameFull: Rapoport AP
      – PersonEntity:
          Name:
            NameFull: Cartron G
      – PersonEntity:
          Name:
            NameFull: Fleury I
      – PersonEntity:
          Name:
            NameFull: Izutsu K
      – PersonEntity:
          Name:
            NameFull: Kamdar M
      – PersonEntity:
          Name:
            NameFull: Mielke S
      – PersonEntity:
          Name:
            NameFull: Barbui AM
      – PersonEntity:
          Name:
            NameFull: Ortega JLR
      – PersonEntity:
          Name:
            NameFull: Nastoupil LJ
      – PersonEntity:
          Name:
            NameFull: Ahmed S
      – PersonEntity:
          Name:
            NameFull: Bar M
      – PersonEntity:
          Name:
            NameFull: Diaz L
      – PersonEntity:
          Name:
            NameFull: Furustrand U
      – PersonEntity:
          Name:
            NameFull: Diab V
      – PersonEntity:
          Name:
            NameFull: Vedal M
      – PersonEntity:
          Name:
            NameFull: Avilion A
      – PersonEntity:
          Name:
            NameFull: Kumar J
      – PersonEntity:
          Name:
            NameFull: Nishii R
      – PersonEntity:
          Name:
            NameFull: Colicino S
      – PersonEntity:
          Name:
            NameFull: Morschhauser F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 03
              Text: 2026 Mar 07
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 407
            – Type: issue
              Value: 10532
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1